Attention Deficit Hyperactivity Disorder Clinical Trial
Official title:
Phase III Study of Autism Co-Morbid for Attention Deficit Hyperactivity Disorder
This is an open-label study of the efficacy of Daytrana (methylphenidate transdermal system)
for the treatment of attention and behavioral symptoms in children with Autism Spectrum
Disorders. Twenty patients will be enrolled and treated with 10-30 mg of Daytrana for a
total of eight weeks. Changes in core hyperactivity, impulsivity, and inattention symptoms,
autism spectrum symptoms and functional outcomes will be assessed. Acceptability of the
transdermal route of administration in this population will also be assessed.
The researchers hypothesize that Daytrana is a safe and effective medication for children
with Autism Spectrum Disorders who have symptoms of inattention, hyperactivity and
impulsivity.
The design will be an open-label trial of eight weeks duration with 20 children with Autism co-morbid for ADHD. The subjects will receive 7 days of 10 mg of Daytrana. The children will be seen weekly for assessment for 4 weeks then every two weeks until the eight week period is complete. After each week of treatment, response will be reassessed and the dose will be increased stepwise to 15 mg, 20 mg, 30 mg unless there are excessive side effects, in which case, the dose will be reduced to the previous dose or the patch wear time may be revised. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06129396 -
Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
| Completed |
NCT04779333 -
Lifestyle Enhancement for ADHD Program 2
|
N/A | |
| Recruiting |
NCT05935722 -
Evaluation of a Home-based Parenting Support Program: Parenting Young Children
|
N/A | |
| Completed |
NCT03148782 -
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
|
N/A | |
| Completed |
NCT04832737 -
Strength-based Treatment Approach for Adults With ADHD
|
N/A | |
| Recruiting |
NCT04631042 -
Developing Brain, Impulsivity and Compulsivity
|
||
| Recruiting |
NCT05048043 -
Development of a Game-supported Intervention
|
N/A | |
| Completed |
NCT03337646 -
Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
|
Phase 4 | |
| Not yet recruiting |
NCT06454604 -
Virtual Reality Treatment for Emerging Adults With ADHD
|
Phase 2 | |
| Not yet recruiting |
NCT06080373 -
Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial
|
N/A | |
| Not yet recruiting |
NCT06406309 -
Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD
|
N/A | |
| Completed |
NCT02477280 -
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance
|
Phase 4 | |
| Completed |
NCT02911194 -
a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)
|
N/A | |
| Completed |
NCT02780102 -
Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD
|
N/A | |
| Completed |
NCT02390791 -
New Technologies to Help Manage ADHD
|
N/A | |
| Completed |
NCT02555150 -
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
|
Phase 3 | |
| Completed |
NCT02473185 -
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest
|
Phase 4 | |
| Completed |
NCT02829970 -
Helping College Students With ADHD Lead Healthier Lifestyles
|
N/A | |
| Recruiting |
NCT04175028 -
Neuromodulation of Executive Function in the ADHD Brain
|
N/A | |
| Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A |